DK1996621T3 - Antibodies to beta-amyloid peptide - Google Patents

Antibodies to beta-amyloid peptide

Info

Publication number
DK1996621T3
DK1996621T3 DK07727401.7T DK07727401T DK1996621T3 DK 1996621 T3 DK1996621 T3 DK 1996621T3 DK 07727401 T DK07727401 T DK 07727401T DK 1996621 T3 DK1996621 T3 DK 1996621T3
Authority
DK
Denmark
Prior art keywords
antibodies
beta
amyloid peptide
amyloid
peptide
Prior art date
Application number
DK07727401.7T
Other languages
Danish (da)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK1996621T3 publication Critical patent/DK1996621T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK07727401.7T 2006-03-30 2007-03-27 Antibodies to beta-amyloid peptide DK1996621T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
PCT/EP2007/052928 WO2007113172A2 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
DK1996621T3 true DK1996621T3 (en) 2010-04-19

Family

ID=38284050

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09178407.4T DK2177536T3 (en) 2006-03-30 2007-03-27 Antibodies to amyloid beta peptide
DK07727401.7T DK1996621T3 (en) 2006-03-30 2007-03-27 Antibodies to beta-amyloid peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK09178407.4T DK2177536T3 (en) 2006-03-30 2007-03-27 Antibodies to amyloid beta peptide

Country Status (33)

Country Link
US (3) US8227576B2 (en)
EP (2) EP1996621B1 (en)
JP (1) JP5103466B2 (en)
KR (2) KR101263294B1 (en)
CN (2) CN103539857A (en)
AR (1) AR060332A1 (en)
AT (1) ATE451392T1 (en)
AU (1) AU2007233831B2 (en)
BR (1) BRPI0709246A2 (en)
CA (1) CA2647808C (en)
CR (1) CR10347A (en)
CY (1) CY1109877T1 (en)
DE (1) DE602007003703D1 (en)
DK (2) DK2177536T3 (en)
EA (1) EA015654B9 (en)
ES (2) ES2338179T3 (en)
HK (2) HK1122311A1 (en)
HR (2) HRP20100115T1 (en)
IL (1) IL193695A (en)
JO (1) JO2576B1 (en)
MA (1) MA30337B1 (en)
MX (1) MX2008012483A (en)
MY (1) MY149630A (en)
NO (1) NO20083793L (en)
NZ (1) NZ571038A (en)
PE (1) PE20080181A1 (en)
PL (2) PL1996621T3 (en)
PT (2) PT1996621E (en)
SI (2) SI1996621T1 (en)
TW (1) TWI385179B (en)
UA (1) UA94734C2 (en)
WO (1) WO2007113172A2 (en)
ZA (1) ZA200807911B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1583562E (en) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, related compounds, and uses thereof
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
CA2589860A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
KR101667623B1 (en) 2005-11-30 2016-10-19 애브비 인코포레이티드 Monoclonal antibodies against amyloid beta protein and uses thereof
PL1954718T3 (en) 2005-11-30 2015-04-30 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
MX2009000476A (en) * 2006-07-14 2009-01-28 Ac Immune Sa Humanized antibody against amyloid beta.
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
DK2182983T3 (en) * 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
DK3216802T3 (en) * 2007-08-20 2021-01-04 Glaxo Group Ltd PRODUCTION PROCEDURE
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
EP2205631B1 (en) * 2007-10-05 2016-11-23 Genentech, Inc. Methods and compositions for diagnosis and treatment of amyloidosis
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
KR101280704B1 (en) 2007-10-12 2013-07-01 에프. 호프만-라 로슈 아게 Protein expression from multiple nucleic acids
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
US8921523B2 (en) * 2007-12-11 2014-12-30 Glaxo Group Limited Humanized anti-beta-amyloid antibodies
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
US20110064821A1 (en) 2008-05-06 2011-03-17 Catchpole Ian Richard Encapsulation of biologically active agents
JP2012505637A (en) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド GLP-1 agonist conjugates and uses thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102307904A (en) 2008-12-05 2012-01-04 安吉奥开米公司 Conjugates of neurotensin or neurotensin analogs and uses thereof
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
RU2012103240A (en) 2009-07-02 2013-08-10 Ангиокем Инк. MULTI-DIMENSIONAL PEPTIDE CONJUGATES AND THEIR APPLICATION
KR101755737B1 (en) 2009-09-11 2017-07-07 프로비오드룩 아게 Heterocyclic derivatives as inhibitors of glutaminyl cyclase
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
MX336196B (en) 2010-04-15 2016-01-11 Abbvie Inc Amyloid-beta binding proteins.
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
US20120171120A1 (en) 2010-11-30 2012-07-05 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
TW201400132A (en) 2012-05-21 2014-01-01 Genentech Inc Methods for improving safety of blood-brain barrier transport
RU2509155C1 (en) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Detection method of proteins in amyloid state, and set for detection of proteins in amyloid state
US20160139118A1 (en) 2013-06-19 2016-05-19 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (en) * 2015-01-04 2015-04-29 东南大学 Single-domain heavy-chain nanobody for amyloid-beta and application of single-domain heavy-chain nanobody
ES2826827T3 (en) 2015-06-15 2021-05-19 Angiochem Inc Methods for the treatment of leptomeningeal carcinomatosis
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
CN111093692A (en) * 2017-06-29 2020-05-01 纽约哥伦比亚大学理事会 Chimeric antibodies for treating amyloid deposition diseases
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
EP3819311A4 (en) * 2018-07-17 2022-08-17 Jiangsu Hengrui Medicine Co., Ltd. Anti-abeta antibody, antigen-binding fragment thereof and application thereof
EP3946605A1 (en) 2019-04-05 2022-02-09 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2023000949A (en) 2020-07-23 2023-02-22 Othair Prothena Ltd Anti-abeta antibodies.
TW202300517A (en) 2021-03-12 2023-01-01 美商美國禮來大藥廠 Anti-amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (en) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 Hybridoma cells producing anti-beta-amyloid antibodies and uses thereof
CN114591917B (en) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 Hybridoma cells producing antibodies that bind beta-amyloid and uses thereof
KR102530956B1 (en) * 2022-09-08 2023-05-11 주식회사 알츠코리아 Alzheimer's disease vaccine composition comprising epitope derived from amyloid beta as effective component and thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
EP2305709A1 (en) * 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
JP2002530122A (en) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド Prevention and treatment of amyloid-related diseases
DK1481992T3 (en) * 2000-02-24 2017-01-30 Washington Univ St Louis Humanized antibodies which sequester amyloid beta peptide
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (en) * 2002-10-08 2004-04-09 Pro Cord Spa BACK OF CHAIR.
JP2006519762A (en) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション Methods for treating Alzheimer's disease using antibodies against amyloid β peptide and compositions thereof

Also Published As

Publication number Publication date
EP2177536B1 (en) 2014-06-04
CA2647808C (en) 2015-11-17
US20140050719A1 (en) 2014-02-20
CY1109877T1 (en) 2014-09-10
EP1996621B1 (en) 2009-12-09
MA30337B1 (en) 2009-04-01
IL193695A (en) 2012-05-31
PL1996621T3 (en) 2010-05-31
PT1996621E (en) 2010-03-08
HRP20100115T1 (en) 2010-04-30
NO20083793L (en) 2008-10-13
KR101263294B1 (en) 2013-06-04
KR20080113273A (en) 2008-12-29
HRP20140618T1 (en) 2014-08-15
MY149630A (en) 2013-09-13
ATE451392T1 (en) 2009-12-15
CN101415729B (en) 2013-09-04
PE20080181A1 (en) 2008-03-16
JP2009531380A (en) 2009-09-03
EP2177536A1 (en) 2010-04-21
AR060332A1 (en) 2008-06-11
JO2576B1 (en) 2011-02-27
US9193784B2 (en) 2015-11-24
CN103539857A (en) 2014-01-29
EA200801842A1 (en) 2009-02-27
IL193695A0 (en) 2011-08-01
SI2177536T1 (en) 2014-09-30
DK2177536T3 (en) 2014-07-14
US20160024197A1 (en) 2016-01-28
TWI385179B (en) 2013-02-11
CA2647808A1 (en) 2007-10-11
AU2007233831A1 (en) 2007-10-11
PL2177536T3 (en) 2014-11-28
JP5103466B2 (en) 2012-12-19
DE602007003703D1 (en) 2010-01-21
EP1996621A2 (en) 2008-12-03
MX2008012483A (en) 2008-10-10
HK1138015A1 (en) 2010-08-13
ES2338179T3 (en) 2010-05-04
AU2007233831B2 (en) 2013-02-14
NZ571038A (en) 2011-03-31
EA015654B1 (en) 2011-10-31
US8227576B2 (en) 2012-07-24
KR20120093400A (en) 2012-08-22
TW200815466A (en) 2008-04-01
EA015654B9 (en) 2012-01-30
WO2007113172A2 (en) 2007-10-11
WO2007113172A3 (en) 2007-11-29
CR10347A (en) 2008-10-29
BRPI0709246A2 (en) 2011-07-12
ES2484967T3 (en) 2014-08-12
SI1996621T1 (en) 2010-04-30
PT2177536E (en) 2014-08-22
HK1122311A1 (en) 2009-05-15
CN101415729A (en) 2009-04-22
US20110142824A1 (en) 2011-06-16
ZA200807911B (en) 2009-11-25
UA94734C2 (en) 2011-06-10

Similar Documents

Publication Publication Date Title
DK1996621T3 (en) Antibodies to beta-amyloid peptide
CY2019004I1 (en) MODIFIED ANTI-IL-23P19 ANTIBODIES
DK2046826T3 (en) Exendin-fusion proteins
DK3118221T3 (en) PROTEINS
DK2059533T3 (en) MULTI-SPECIFIC ANTIBODIES
DK2066695T3 (en) ANTI-myostatin ANTIBODIES
DK1999154T3 (en) MANUFACTURED HETERODIMERED PROTEIN DOMAINS
ATE452839T1 (en) CAPSULE WITH REDUCED AFTER-DRIP
DK2383297T3 (en) Optimized antibodies targeting CD19
ES1063346Y (en) WALKER
LU92389I2 (en) cysteamine
DE602007012130D1 (en) MODIFIED FLAVIN-ADENINE-DINUCLEOTIDE-DEPENDENT GLUCOSE-DEHYDROGENASE
BRPI0814971A2 (en) PROTEIN
BRPI0911743A2 (en) "peptide"
DK2035451T3 (en) Insulinoptrop peptide synthesis
FR2909092B1 (en) NEW ANTI-PROLIFERATION ANTIBODIES
NO2022038I1 (en) ropeginterferon alfa-2b
DE602007008903D1 (en) AUSPUFFROHR STRUCTURE
BRPI0820750A2 (en) Cysteine-free cyclic protein
DE112007003333A5 (en) fermenter
DE502007004910D1 (en) turbocharger
DK2010805T3 (en) SEAL
FI20060917A0 (en) synchronous
DK2081952T3 (en) PEPTIDES
DE112008000091A5 (en) Mass bond